{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:22:00Z","timestamp":1779340920282,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RO1 GM95606"],"award-info":[{"award-number":["RO1 GM95606"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Utah Research Foundation"},{"DOI":"10.13039\/501100004396","name":"Thailand Research Fund","doi-asserted-by":"publisher","award":["PHD\/0139\/2557"],"award-info":[{"award-number":["PHD\/0139\/2557"]}],"id":[{"id":"10.13039\/501100004396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","award":["P30 CS042014"],"award-info":[{"award-number":["P30 CS042014"]}],"id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jconrel.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T02:31:00Z","timestamp":1542594660000},"page":"84-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs"],"prefix":"10.1016","volume":"293","author":[{"given":"Lian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirima","family":"Soodvilai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praneet","family":"Opanasopit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jind\u0159ich","family":"Kope\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.11.015_bb0005","doi-asserted-by":"crossref","first-page":"e2540","DOI":"10.1038\/cddis.2016.461","article-title":"MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy","volume":"8","author":"Jin","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0010","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/onc.2016.331","article-title":"FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0015","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/0008-5472.CAN-06-3066","article-title":"Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K\/mTOR\/ETS2 pathway","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0020","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrc1296","article-title":"Targeting the checkpoint kinases: Chemosensitization versus chemoprotection","volume":"4","author":"Zhou","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0025","doi-asserted-by":"crossref","first-page":"15095","DOI":"10.1073\/pnas.2435285100","article-title":"Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy","volume":"100","author":"Wang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0030","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0035","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","article-title":"Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances","volume":"194","author":"Gandhi","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","article-title":"Molecular mechanisms of drug resistance","volume":"205","author":"Longley","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0050","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: Advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0065","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1002\/adfm.201501248","article-title":"Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs","volume":"25","author":"Li","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2016.04.021","article-title":"Time-staggered delivery of docetaxel and H1-S6A, F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting","volume":"232","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0075","first-page":"1789","article-title":"Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis","volume":"60","author":"Arola","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nnano.2007.418","article-title":"Nanomagnetic actuation of receptor-mediated signal transduction","volume":"3","author":"Mannix","year":"2008","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14179","article-title":"Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis","volume":"8","author":"Mitchell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0095","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ange.200906232","article-title":"Drug-free macromolecular therapeutics: Induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface","volume":"49","author":"Wu","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2014.04.028","article-title":"Apo2L\/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity","volume":"26","author":"Graves","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201700544","article-title":"Frizzled7 antibody-functionalized nanoshells enable multivalent binding for wnt signaling inhibition in triple negative breast cancer cells","volume":"13","author":"Riley","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0110","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acsnano.8b00797","article-title":"Amplification of CD20 cross-linking in rituximab-resistant B-lymphoma cells enhances apoptosis induction by drug-free macromolecular therapeutics","volume":"12","author":"Li","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201700196","article-title":"Drug-free macromolecular therapeutics induce apoptosis via calcium influx and mitochondrial signaling pathway","volume":"18","author":"Li","year":"2018","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1021\/nn4053827","article-title":"Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis","volume":"8","author":"Chu","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0125","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4161\/cbt.9.8.11264","article-title":"Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types","volume":"9","author":"Kaplan-Lefko","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0130","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-05-0554","article-title":"Generation of rituximab polymer may cause hyper-cross-linking\u2013induced apoptosis in non-Hodgkin's lymphomas","volume":"11","author":"Zhang","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.02.037","article-title":"Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery","volume":"277","author":"Ichimizu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2014.11.008","article-title":"Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer","volume":"197","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1021\/bc1002295","article-title":"Targeted albumin-based nanoparticles for delivery of amphipathic drugs","volume":"22","author":"Xu","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0155","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2005.02720.x","article-title":"Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis","volume":"139","author":"Janas","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2567.2005.02213.x","article-title":"Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking","volume":"116","author":"Unruh","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0165","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/cbic.201500278","article-title":"Super-resolution imaging and quantitative analysis of membrane protein\/lipid raft clustering mediated by cell-surface self-assembly of hybrid nanoconjugates","volume":"16","author":"Hartley","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0170","first-page":"1065","article-title":"S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine","volume":"61","author":"Shi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0175","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0180","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1101\/gad.1662308","article-title":"Akt-dependent regulation of NF-\u03baB is controlled by mTOR and Raptor in association with IKK","volume":"22","author":"Dan","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0185","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14292","article-title":"Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma","volume":"8","author":"Mizrachi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0195","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2007-04-085092","article-title":"PKC \u03b6\u2013mTOR pathway: A new target for rituximab therapy in follicular lymphoma","volume":"111","author":"Leseux","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0205","doi-asserted-by":"crossref","first-page":"31831","DOI":"10.1074\/jbc.M009374200","article-title":"Phosphatidylinositol 3-kinase-dependent extracellular calcium influx is essential for CX3CR1-mediated activation of the mitogen-activated protein kinase cascade","volume":"276","author":"Kansra","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0210","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/adma.201404308","article-title":"An imagable and photothermal \u201cabraxane-like\u201d nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors","volume":"27","author":"Chen","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0215","article-title":"Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.11.015_bb0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40591-016-0048-8","article-title":"Albumin-based drug delivery: Harnessing nature to cure disease","volume":"4","author":"Larsen","year":"2016","journal-title":"Mol. Cell. Ther."},{"key":"10.1016\/j.jconrel.2018.11.015_bb0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.molpharmaceut.5b00605","article-title":"Neonatal Fc receptor binding tolerance toward the covalent conjugation of payloads to cysteine 34 of human albumin variants","volume":"13","author":"Petersen","year":"2015","journal-title":"Mol. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918306527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918306527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T18:08:49Z","timestamp":1545415729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918306527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":46,"alternative-id":["S0168365918306527"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.11.015","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}